Changchun BCHT Biotechnology Co. A

SHG:688276 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.06 Billion
CN¥7.78 Billion CNY
Market Cap Rank
#12973 Global
#3279 in China
Share Price
CN¥18.81
Change (1 day)
-0.58%
52-Week Range
CN¥18.53 - CN¥25.44
All Time High
CN¥117.52
About

Changchun BCHT Biotechnology Co. Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of human vaccines in China and internationally. The company's products include herpes zoster vaccine; varicella vaccine; live, nasal, and freeze-dried influenza vaccine; and rabies vaccine (vero cell) for humans. Changchun BCHT Biotechnology Co. Ltd. was founded in 200… Read more

Changchun BCHT Biotechnology Co. A (688276) - Total Liabilities

Latest total liabilities as of September 2025: CN¥1.25 Billion CNY

Based on the latest financial reports, Changchun BCHT Biotechnology Co. A (688276) has total liabilities worth CN¥1.25 Billion CNY as of September 2025.

Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Changchun BCHT Biotechnology Co. A - Total Liabilities Trend (2017–2024)

This chart illustrates how Changchun BCHT Biotechnology Co. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.

Changchun BCHT Biotechnology Co. A Competitors by Total Liabilities

The table below lists competitors of Changchun BCHT Biotechnology Co. A ranked by their total liabilities.

Liability Composition Analysis (2017–2024)

This chart breaks down Changchun BCHT Biotechnology Co. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 1.39 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.32 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.24 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Changchun BCHT Biotechnology Co. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Changchun BCHT Biotechnology Co. A (2017–2024)

The table below shows the annual total liabilities of Changchun BCHT Biotechnology Co. A from 2017 to 2024.

Year Total Liabilities Change
2024-12-31 CN¥987.12 Million -3.78%
2023-12-31 CN¥1.03 Billion +41.69%
2022-12-31 CN¥724.02 Million -4.36%
2021-12-31 CN¥757.05 Million +10.11%
2020-12-31 CN¥687.57 Million +20.56%
2019-12-31 CN¥570.29 Million -6.62%
2018-12-31 CN¥610.74 Million +12.59%
2017-12-31 CN¥542.45 Million --